[email protected] 欢迎来到OAJRC平台！

国际遗传前沿杂志

International Journal of Genetics Frontiers

您当前位置：首页 > 精选文章

International Journal of Genetics Frontiers. 2020; 1: (1) 5; 10.12208/j.ijgf.20200005 .

PDF 全文下载
总浏览量: 2810

Interleukin-6 (-174 G/C) and Hepcidin HAMP (-582A/G) Gene Polymorphisms among Sudanese Patients with Anemia of Chronic Kidney Disease Treated with Erythropoietin
促红细胞生成素治疗苏丹慢性肾脏病贫血患者的白细胞介素-6（-174G/C）和铁调素HAMP（-582A/G）基因多态性

作者： Khalid Mohamed Khalid Elhussain *, Amged Husssen Abdelrhman, Enaam Abdelrhman Abdelgadir

奥姆杜尔曼伊斯兰大学血液学和免疫血液学系，奥德穆尔曼·阿赫利亚大学医学部，非洲国际大学医学检验科学学院

奥姆杜尔曼伊斯兰大学血液学和免疫血液学系

苏丹铝大学医学院病理学系

*通讯作者： Khalid Mohamed Khalid Elhussain,单位：奥姆杜尔曼伊斯兰大学血液学和免疫血液学系，奥德穆尔曼·阿赫利亚大学医学部，非洲国际大学医学检验科学学院；

引用本文: Khalid Mohamed Khalid Elhussain, Amged Husssen Abdelrhman, Enaam Abdelrhman Abdelgadir 促红细胞生成素治疗苏丹慢性肾脏病贫血患者的白细胞介素-6（-174G/C）和铁调素HAMP（-582A/G）基因多态性[J]. 国际遗传前沿杂志, 2020; 1: (1) : 24-29.

Published: 2020/6/17 11:29:23

摘要

目的这是一项病例对照研究，用于通过聚合酶链反应测定苏丹红细胞生成素治疗的慢性肾脏病贫血患者中白细胞介素6（-174 G / C）和铁调素HAMP（-582A / G）基因多态性的频率反应限制片段长度多态性（PCR / RFLP）。结果 RBCS曲线水平显着降低：观察到具有CKD和RBCS曲线的患者的RBC计数，Hb和PCV。结果显示苏丹ACKD患者中IL-6基因和铁调素（HAMP）基因启动子的多态性（SNP）。在Hepcidin HAMP（-582A / G）（SNP）AA基因型70（35％），AG 23（11.5）和GG 7（3.5％）中存在IL-6（-174G / C）（SNP）依赖透析的患者和200名对照组的AA 166（41.5％），AG 34（8.5％）和GG 0（0％），等位基因A在受ACKD影响的患者中更为频繁。

关键词： 贫血;白介素6基因多态性； hepcidin HAMP基因多态性；慢性肾脏病患者

Abstract

Objectives. This is a case controls study used to determine the frequency of Interleukin-6 (-174 G/C) and hepcidin HAMP (-582A/G) gene polymorphisms among Sudanese patients with anemia of chronic kidney disease treated with erythropoietin by using the Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR/RFLP).
Results. Significantly decreased levels in RBCS profile: RBCs count, Hb and PCVin patients with CKD and RBCS profile were observed. The polymorphisms (SNP) of the IL-6 gene and hepcidin (HAMP) gene promoter in Sudanese patients with ACKD were showed. the IL-6 (-174G/C) (SNP) was present in the hepcidin HAMP (-582A/G) (SNP) AA genotype 70 (35%), AG 23 (11.5) and GG 7 (3.5%) in 100 patients dialysis dependent and AA 166 (41.5%), AG 34 (8.5%) and GG 0 (0%) in 200 control subjects, and the allele A are more frequent in patients affected by ACKD.

Key words： Anemia; Interleukin-6 gene polymorphism; hepcidin HAMP gene polymorphism; Chronic kidney disease patients

参考文献 References

[1] Hentze, M. W., Muckenthaler, M. U. & Andrews, N. C. (2004). Balancing acts: molecular control of mammalian iron metabolism. Cell, 117, 285-297. .

[2] Liao, G., Xiang, J., Huang, X. & Yang, Y. (2012). A New “Mix-confined” Repeated Load Test for Evaluating Permanent Deformation of Asphalt Mixture. Journal of Testing and Evaluation, 40, 1177-1185. .

[3] Roy, A., Kucukural, A. & Zhang, Y. (2010). I-TASSER: a unified platform for automated protein structure and function prediction. Nature protocols, 5, 725. .

[4] Tim Goodnough L., Comin-Colet J., Leal-Noval S., et al. (2017). Management of anemia in patients with congestive heart failure.Am J Hematol,92 (1) : 88-93.

[5] Muckenthaler M. U., Rivella S., Hentze M. W., Galy B. (2017). A red carpet for iron metabolism.Cell,168 (3) : 344-361.

[6] Canali S., Core A. B., Zumbrennen-Bullough K. B., et al. (2016). Activin B induces noncanonical SMAD1/5/8 signaling via BMP type i receptors in hepatocytes: evidence for a role in hepcidin induction by inflammation in male mice.Endocrinology,157 (3) : 1146-1162.

[7] Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., Ward, D. M., Ganz, T. & Kaplan, J. (2004). Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science, 306, 2090-2093. .

[8] Nemeth, E. & Ganz, T. (2009). The role of hepcidin in iron metabolism. Acta haematologica, 122, 78-86. .

[9] Aschemeyer S., Qiao B., Stefanova D., et al. (2018). Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin. Blood,131 (8) : 899-910.

[10] Hunter, H. N., Fulton, D. B., Ganz, T. & Vogel, H. J. (2002). The solution structure of human hepcidin, a peptide hormone with antimicrobial activity that is involved in iron uptake and hereditary hemochromatosis. Journal of Biological Chemistry, 277, 37597-37603. .

[11] Taga, T., Hibi, M., Hirata, Y., Yamasaki, K., Yasukawa, K., Matsuda, T., Hirano, T. & Kishimoto, T. (1989). Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell, 58, 573-581. .

[12] Hirano, T., Akira, S., Taga, T. & Kishimoto, T. (1990). Biological and clinical aspects of interleukin 6. Immunology today, 11, 443-449. .

[13] Nishimoto, N. & Kishimoto, T. (2006). Interleukin 6: from bench to bedside. Nature Reviews Rheumatology, 2, 619. .

[14] Solak A. A., SöDERKVIST, B. K., MEDIN, C., HYLANDER, B. & HEIWE, S. (2012). Health-related quality of life in different stages of chronic kidney disease and at initiation of dialysis treatment. Health and quality of life outcomes, 10, 71. .

[15] Nairz M., Theurl I., Swirski F. K., Weiss G. (2017). “Pumping iron”-how macrophages handle iron at the systemic, microenvironmental, and cellular levels.Pflugers Arch,469 (3-4) : 397-418.

[16] Theurl I., Hilgendorf I., Nairz M., et al. (2016). On-demand erythrocyte disposal and iron recycling requires transient macrophages in the liver.Nat Med,22 (8) : 945-951.

[17] Khalil S., Delehanty L., Grado S, et al. (2018). Iron modulation of erythropoiesis is associated with Scribble-mediated control of the erythropoietin receptor.J Exp Med,215 (2) : 661-679.

[18] Zhang S., Macias-Garcia A., Velazquez J., Paltrinieri E., Kaufman R. J., Chen J. J. (2018). HRI coordinates translation by eIF2αP and mTORC1 to mitigate ineffective erythropoiesis in mice during iron deficiency.Blood,131 (4) : 450-461.

[19] Latour C, Wlodarczyk MF, Jung G, et al. (2017). Erythroferrone contributes to hepcidin repression in a mouse model of malarial anemia.Haematologica,102 (1) : 60-68.

[20] Docherty A. B., Turgeon A. F. Walsh T. S. (2018). Best practice in critical care: anaemia in acute and critical illness.Transfus Med,28 (2) : 181-189.

[21] Xu, J. Q., Mattock, M., Chusney, G. & Burt, D. (1997). NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia, 40, 1286. .

[22] [22]Travis, S., González-Quintela, A., Campos, J., Quinteiro, C., Domínguez, F. & Loidi, L. (2010). Genetic study of the hepcidin gene (HAMP) promoter and functional analysis of the c.-582A> G variant. BMC genetics, 11, 110. .

Interleukin-6 (-174 G/C) and Hepcidin HAMP (-582A/G) Gene Polymorphisms among Sudanese Patients with Anemia of Chronic Kidney Disease Treated with Erythropoietin促红细胞生成素治疗苏丹慢性肾脏病贫血患者的白细胞介素-6（-174G/C）和铁调素HAMP（-582A/G）基因多态性

摘要

Abstract

参考文献 References

Interleukin-6 (-174 G/C) and Hepcidin HAMP (-582A/G) Gene Polymorphisms among Sudanese Patients with Anemia of Chronic Kidney Disease Treated with Erythropoietin
促红细胞生成素治疗苏丹慢性肾脏病贫血患者的白细胞介素-6（-174G/C）和铁调素HAMP（-582A/G）基因多态性